Skip to main content

Michael Henderson

Michael Henderson

Michael Henderson

CEO

Michael Henderson, M.D., joined Apogee in September 2022 and serves as CEO and board member. He is a proven biotechnology industry leader with expertise in business leadership, drug development and commercial strategy. He also serves on the board of Spyre Therapeutics. Prior to joining Apogee, Michael spearheaded the creation of more than 20 companies, launched 40 drug development programs and led two teams to FDA approvals. Michael received his B.A. from Harvard University and holds an M.D. from Stanford University.